Spyre Therapeutics (SYRE) Preferred Shares (2015 - 2026)

Spyre Therapeutics (SYRE) has 4 years of Preferred Shares data on file, last reported at $146.4 million in Q1 2026.

• Quarterly Preferred Shares changed N/A year-over-year to $146.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $146.4 million (changed N/A YoY) and the FY2025 annual result came in at $9.4 million, changed 0.0% from the prior year.
• Preferred Shares improved to $146.4 million in Q1 2026, from $9.4 million in the prior quarter.
• In the past five years, Preferred Shares ranged from a high of $184.9 million in Q1 2024 to a low of $9.4 million in Q4 2024.
• A 3-year average of $117.0 million and a median of $146.4 million in 2024 frame the typical range for Preferred Shares.
• The widest YoY moves for Preferred Shares: up 0.0% in 2025, down 0.0% in 2025.
• Tracing SYRE's Preferred Shares over 3 years: stood at $9.4 million in 2024, then changed by 0.0% to $9.4 million in 2025, then jumped by 1458.54% to $146.4 million in 2026.
• The last three Preferred Shares figures came in at $146.4 million (Q1 2026), $9.4 million (Q4 2025), and $146.4 million (Q3 2025), per Business Quant data.